Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy
Open Access
- 13 January 2023
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 31 (3) , 686-700
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Cancer Institute (1R01CA219871-01 A1, 5R01CA206012-04)
- Burroughs Wellcome Fund
- National Blood Foundation (2019-BP-00204)
- Departament d'Empresa i Coneixement, Generalitat de Catalunya
This publication has 56 references indexed in Scilit:
- Vancomycin Revisited – 60 Years LaterFrontiers in Public Health, 2014
- Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T CellsFrontiers in Immunology, 2013
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- Systemic absorption of oral vancomycin in patients with Clostridium difficile infectionScandinavian Journal of Infectious Diseases, 2011
- MHC class I antigen presentation: learning from viral evasion strategiesNature Reviews Immunology, 2009
- Biochemical Differentiation and Comparison ofDesulfovibrioSpecies and Other Phenotypically Similar GeneraJournal of Clinical Microbiology, 2005
- Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanomaCellular Immunology, 2004
- Comparison of two oral formulations of vancomycin for treatment of diarrhoea associated with Clostridium difficileJournal of Antimicrobial Chemotherapy, 1989
- Safety of Oral Vancomycin in Functionally Anephric PatientsAntimicrobial Agents and Chemotherapy, 1978
- ORAL VANCOMYCIN FOR ANTIBIOTIC-ASSOCIATED PSEUDOMEMBRANOUS COLITISThe Lancet, 1978